Executives of Clovis Oncology Inc. look to have an uphill battle convincing members of the Oncology Drugs Advisory Committee (ODAC) Tuesday of the clinical benefit of rociletinib in a subset of NSCLC patients, based on briefing docs released Friday raising questions as to both the drug’s safety and efficacy.